Clinical and genomic characteristics between DDR germline and somatic mutations in pan-cancer. Programmed cell death ligand 1 (PD-L1) expression landscape and its relationship with tumor mutational ...

Although hypomethylating agents are currently used to treat patients with cancer, whether they can also reactivate and up-regulate oncogenes is not well elucidated. By combining analysis of patient ...

Table 1. FDA-Approved Companion Diagnostic Tests and Therapy of Rare Oncogenic Driver Mutations in NSCLC Table 2. Pivotal Trials of Oncogenic Driver Mutations in NSCLC Ceritinib was studied in a ...